Cognition Therapeutics, Inc. (CGTX)

Over the past six months, Cognition Therapeutics participated in the 37th Annual Piper Sandler Healthcare Conference in November 2025. On December 1, 2025, the company presented its Phase 3 plan for zervimesine (CT1812) in Alzheimer's disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference. On December 3, 2025, Cognition Therapeutics announced that its expanded access program for zervimesine in dementia with Lewy bodies reached full enrollment. On December 29, 2025, Weiss Ratings restated a "sell (d-)" rating on the stock. On January 6, 2026, Cognition Therapeutics published Phase 2 clinical results demonstrating zervimesine's potential to slow the progression of dementia with Lewy bodies. On January 21, 2026, the company held a Type C meeting with the FDA to discuss plans for a proposed Phase 2b study of zervimesine in dementia with Lewy bodies. On January 27, 2026, Cognition Therapeutics completed its Type C meeting with the FDA for zervimesine in dementia with Lewy bodies. On February 5, 2026, the company extended its expanded access program for zervimesine in dementia with Lewy bodies. On February 6, 2026, Brookline Capital Management upgraded the stock to a "Strong-Buy". The stock has experienced volatility, including technical selling pressure and declines amid broader biotech sector weakness.

As a clinical-stage biopharmaceutical company with no currently approved commercial products, traditional demand seasonality does not directly apply to Cognition Therapeutics. The demand for its lead candidate, zervimesine, is driven by the progression of its clinical trials and regulatory milestones for chronic neurodegenerative diseases like Alzheimer's and dementia with Lewy bodies, rather than seasonal fluctuations in patient needs. The company's focus is on developing novel therapies for unmet medical needs, which drives investment and research in the clinical-stage biotechnology market.

Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative diseases affecting the central nervous system and retina. Its lead product candidate, zervimesine (CT1812), is in Phase 2 clinical trials for Alzheimer's disease and dementia with Lewy bodies (DLB). The company discontinued a Phase 2 study for geographic atrophy secondary to dry age-related macular degeneration (dry AMD) to prioritize Alzheimer's and DLB programs. Zervimesine is designed to interact with the sigma-2 receptor complex, potentially slowing disease progression by interrupting the toxic effects of proteins like amyloid-beta (Aβ) and alpha-synuclein.

Cognition Therapeutics is headquartered in Purchase, New York, in the United States. Its clinical trials, including the SHINE, SHIMMER, and START studies, are conducted in the U.S. The company's expanded access program for dementia with Lewy bodies involves multiple U.S. clinical sites. Cognition Therapeutics plans to seek alignment with the European Medicines Agency (EMA) regarding global registrational plans for Alzheimer's disease, indicating potential future international reach.

Cognition Therapeutics' brand reputation is shaped by its clinical progress and analyst sentiment. The company has received a consensus "Buy" rating from analysts, with some assigning "Strong Buy" ratings, and analysts have an average target price suggesting significant upside potential. Positive clinical trial results, such as those from the Phase 2 SHIMMER DLB study, contribute positively to its reputation. The extension of the expanded access program for zervimesine in DLB has also been viewed positively. However, as a clinical-stage company, it faces inherent risks related to clinical trial outcomes, regulatory approvals, and financing, which can impact investor sentiment.

Cognition Therapeutics has a diverse ownership structure, including institutional, individual, and retail investors. Approximately 24.09% of the company's stock is held by institutional shareholders, and 29.34% by insiders. Major institutional owners include BIOS Capital Management, LP, Vanguard Group Inc, Davenport & Co LLC, Tang Capital Management Llc, Chescapmanager LLC, BlackRock, Inc., Jane Street Group, Llc, Renaissance Technologies Llc, and Geode Capital Management, Llc. Key individual owners and insiders include Aaron G.L. Fletcher, Lisa Ricciardi (CEO), Leslie W. Kreis, Ogden Cap Associates LLC, and BIOS Memory Spv I LP.